Striatal M4 Receptors Mediate M4 PAM Antipsychotic-like Efficacy Independently of Normalizing Striatal Dopamine Release
Muscarinic acetylcholine receptor (mAChR) drugs have emerged as a promising new class of antipsychotics, highlighted by the FDA approval of Cobenfy, the first treatment for schizophrenia that does not directly target dopamine receptors. The M4 receptor subtype is thought to be a key mediator of antipsychotic-like effic...